Gastric inhibitory polypeptide

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

(Redirected from Gastric inhibitory peptide)
Jump to: navigation, search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Gastric inhibitory polypeptide
Identifiers
Symbol GIP
Entrez 2695
HUGO 4270
OMIM 137240
RefSeq NM_004123
UniProt P09681
Other data
Locus Chr. 17 q21.3-q22

WikiDoc Resources for

Gastric inhibitory polypeptide

Articles

Most recent articles on Gastric inhibitory polypeptide

Most cited articles on Gastric inhibitory polypeptide

Review articles on Gastric inhibitory polypeptide

Articles on Gastric inhibitory polypeptide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gastric inhibitory polypeptide

Images of Gastric inhibitory polypeptide

Photos of Gastric inhibitory polypeptide

Podcasts & MP3s on Gastric inhibitory polypeptide

Videos on Gastric inhibitory polypeptide

Evidence Based Medicine

Cochrane Collaboration on Gastric inhibitory polypeptide

Bandolier on Gastric inhibitory polypeptide

TRIP on Gastric inhibitory polypeptide

Clinical Trials

Ongoing Trials on Gastric inhibitory polypeptide at Clinical Trials.gov

Trial results on Gastric inhibitory polypeptide

Clinical Trials on Gastric inhibitory polypeptide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gastric inhibitory polypeptide

NICE Guidance on Gastric inhibitory polypeptide

NHS PRODIGY Guidance

FDA on Gastric inhibitory polypeptide

CDC on Gastric inhibitory polypeptide

Books

Books on Gastric inhibitory polypeptide

News

Gastric inhibitory polypeptide in the news

Be alerted to news on Gastric inhibitory polypeptide

News trends on Gastric inhibitory polypeptide

Commentary

Blogs on Gastric inhibitory polypeptide

Definitions

Definitions of Gastric inhibitory polypeptide

Patient Resources / Community

Patient resources on Gastric inhibitory polypeptide

Discussion groups on Gastric inhibitory polypeptide

Patient Handouts on Gastric inhibitory polypeptide

Directions to Hospitals Treating Gastric inhibitory polypeptide

Risk calculators and risk factors for Gastric inhibitory polypeptide

Healthcare Provider Resources

Symptoms of Gastric inhibitory polypeptide

Causes & Risk Factors for Gastric inhibitory polypeptide

Diagnostic studies for Gastric inhibitory polypeptide

Treatment of Gastric inhibitory polypeptide

Continuing Medical Education (CME)

CME Programs on Gastric inhibitory polypeptide

International

Gastric inhibitory polypeptide en Espanol

Gastric inhibitory polypeptide en Francais

Businness

Gastric inhibitory polypeptide in the Marketplace

Patents on Gastric inhibitory polypeptide

Experimental / Informatics

List of terms related to Gastric inhibitory polypeptide

Gastric inhibitory polypeptide (GIP), also known as the glucose-dependent insulinotropic peptide is a member of the secretin family of hormones.

GIP, along with glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), belong to a class of molecules referred to as incretins

Synthesis and transport

GIP is derived from a 153-amino acid proprotein encoded by the GIP gene and circulates as a biologically active 42-amino acid peptide. It is synthesized by K cells, which are found in the mucosa of the duodenum and the jejunum of the gastrointestinal tract.

Like all hormones, it is transported by blood.

Gastric inhibitory polypeptide receptors are seven-transmembrane proteins found on beta-cells in the pancreas.

Function

It has traditionally been called gastrointestinal inhibitory peptide or gastric inhibitory peptide and was believed to neutralize stomach acid to protect the small intestine from acid damage, reduce the rate at which food is transferred through the stomach, and inhibit the GI motility and secretion of acid. However, it was discovered that these effects are only achieved with higher-than-normal physiological level, and that these results naturally occur in the body through a similar hormone, secretin.

It is now believed that the function of GIP is to induce insulin secretion, which is primarily stimulated by hyperosmolarity of glucose in the duodenum. After this discovery, some researchers prefer the new name of glucose-dependent insulinotropic peptide, while retaining the Acronym "GIP." The amount of insulin secreted is greater when glucose is administered orally than intravenously.

GIP is also thought to have significant effects on fatty acid metabolism through stimulation of lipoprotein lipase activity in adipocytes. GIP release has been demonstrated in the ruminant animal and may play a role in nutrient partitioning in milk production (lipid metabolism). GIP is secreted in response to the first maternal feed (colostrum) in goat kids-gip being measured via umbilical vein before its closure. For ethical reasons GIP secretion has only been demonstrated in humans at approx 10 days of age. In respect to the role of GIP in lipid metabolism, supraphysiological levels have shown a lipogenic action, however the action of collagenase in experimental protocols is known to degrade GIP/ GIP receptors. GIP is part of the diffuse endocrine system and consequently difficult to demonstrate physiological or clinical effects. In comparison to insulin its effects are very subtle.

Pathology

It has been found that Type 2 diabetics are not responsive to GIP. In a research involving knockout mice, it was found that absence of the GIP receptors correlates with resistance to obesity.

References


External links

de:Glukoseabhängiges insulinotropes Peptid
WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
In other languages